D. -H. Yang

Supporting Information Filename Description plb13637-sup-0001-Supinfo.docxWord 2007 document , 8.4 MB Table S1. Basic information on the 24 species selected in this study. Table S2. Two-way anova results for each trait. Table S3. Blomberg's K and P-values for phylogenetic signals of 29 floral traits. Table S4. Coefficients of Pearson's correlation (lower left) and phylogenetic independent contrasts (upper right) for pairwise traits in 24 species. Table S5.

Background: In patients (pts) with non-metastatic GC, MMT added to surgery improves the cure rate. The MMT includes adjuvant chemoradiation (ACR), neoadjuvant chemoradiation (NACR), and perioperative chemotherapy (CT). We used the NCDB data to compare different MMT in pts with non-metastatic GC. Methods: A total of 79369 pts with non-metastatic GC diagnosed 2004- 2013 were identified. Pts with known tumor site who underwent surgery and received MMT were selected for this analysis.

Patients and methods We assessed the minimal residual disease (MRD)-based effect and long-term outcome of first-line incorporation of dasatinib (100 mg once daily) into chemotherapy alternatively for adults with Ph-positive ALL. The primary end point was the major molecular response (MMR) rate by the end of the second dasatinib cycle. Patients with a donor proceeded to allogeneic stem cell transplantation (SCT) as early as possible.